Everolimus for advanced breast cancer: Is the histological subtype important?

被引：0
|
作者：
Vargas, Alicia
Flores Paco, Pablo
De La Haba, Juan
Morales-Estevez, Cristina
Rodriguez-Alonso, Beatriz
Porras, Ignacio
de la Cruz-Merino, Luis
Munoz, Clara
Lorente, Margarita
Gonzalez Flores, Encarnacion
Sanchez-Rovira, Pedro
Arenas, Rafael
Armenta, Ana
Aranda, Enrique
机构：
[1] Univ Reina Sofia Hosp, Cordoba, Spain
[2] Inst Maimonides Invest Biomed Cordoba IMIBIC, Cordoba, Spain
[3] Univ Cordoba, Univ Reina Sofia Hosp, Cordoba, Spain
[4] GEICAM Spanish Breast Canc Grp, Cordoba, Spain
[5] Hosp Univ Virgen Macarena, Seville, Spain
[6] Virgen Macarena Univ Hosp, Seville, Spain
[7] Virgen de las Nieves Univ Hosp, Granada, Spain
[8] Virgen de las Nieves Hosp, Granada, Spain
[9] Hosp Univ Jaen, Jaen, Spain
[10] GEICAM Spanish Breast Canc Grp, Jaen, Spain
[11] Univ Reina Sofia Hosp, Dept Med Oncol, Cordoba, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13165
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Flipi and histological subtype are the most important predicting factors of histological transformation (HT) in follicular lymphoma (FL)
    Giné, E
    López-Guillermo, A
    Montoto, S
    Bosch, F
    Villamor, N
    Muntañola, A
    Arenillas, L
    Colomo, L
    Campo, E
    Montserrat, E
    ANNALS OF ONCOLOGY, 2005, 16 : 106 - 106
  • [42] Everolimus in the Treatment of Metastatic Breast Cancer
    Royce, Melanie E.
    Osman, Diaa
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2015, 9 : 73 - 79
  • [43] Everolimus in Breast Cancer: The Role of the Pharmacist
    Dorris, John R., III
    Jones, Suzanne
    ANNALS OF PHARMACOTHERAPY, 2014, 48 (09) : 1194 - 1201
  • [44] Evaluating everolimus for the treatment of breast cancer
    Moreau-Bachelard, Camille
    Robert, Marie
    Gourmelon, Carole
    Bourbouloux, Emmanuelle
    Patsouris, Anne
    Frenel, Jean-Sebastien
    Campone, Mario
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (10) : 1105 - 1111
  • [45] Ductal carcinoma in situ of the breast: Reproducibility of histological subtype analysis
    Scott, MA
    Lagios, MD
    Axelsson, K
    Rogers, LW
    Anderson, TJ
    Page, DL
    HUMAN PATHOLOGY, 1997, 28 (08) : 967 - 973
  • [46] Initial systemic treatment choices by subtype of advanced breast cancer in 2007-2017, a study of the southeast Netherlands advanced breast cancer (SONABRE) registry
    Geurts, Sandra M. E.
    Ibragimova, Khava I. E.
    Erdkamp, Frans
    Vriens, Birgit E. P. J.
    Dercksen, M. Wouter
    den Boer, Marien O.
    Pepels, Manon J. A. E.
    Tilli, Dominique
    de Boer, Maaike
    Tjan-Heijnen, Vivianne C. G.
    CANCER RESEARCH, 2020, 80 (04)
  • [47] Real world experience with exemestane and everolimus for advanced HR-positive breast cancer.
    Wang, Ying
    Le, Dan
    Camateros, Pierre
    Lohrisch, Caroline A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Final results of a phase 1 evaluation of niraparib and everolimus in advanced ovarian and metastatic breast cancer
    Rojas-Espaillat, Luis
    Starks, David
    Williams, Casey
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S159 - S159
  • [49] Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology
    Salhia, Bodour
    Tapia, Coya
    Ishak, Elia A.
    Gaber, Salwa
    Berghuis, Bree
    Hussain, Khateeb H.
    DuQuette, Rachelle A.
    Resau, James
    Carpten, John
    BMC WOMENS HEALTH, 2011, 11
  • [50] Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology
    Bodour Salhia
    Coya Tapia
    Elia A Ishak
    Salwa Gaber
    Bree Berghuis
    Khateeb H Hussain
    Rachelle A DuQuette
    James Resau
    John Carpten
    BMC Women's Health, 11
12345